With hypoxia, seconds make the difference between life and death. We are committed to bridging those moments through the structure of co-polymers. Based on Dr. David Platt's groundbreaking research in carbohydrate chemistry, Bioxytran, Inc is developing treatments for stroke and many other medical situations related to hypoxic conditions.
Our unique technologies are intended for those suffering from stroke, ischemia, or in need of wound healing. Learn more about these conditions.
The key is BioXyTran's two workhorses: BXT-25 and BXT-252. Both drugs are designed to oxygenate ischemic (reduced blood flow) regions of the body and could provide sufferers valuable aid.
Bioxytran Inc. (BIXT) has a novel drug for stroke patients that can restore the supply of oxygen to the brain. Strokes effects over 900,000 people per year and the indirect costs of stroke due to disability and special services are over $22 billion annually.
As of last November, the American College of Cardiology and American Heart Association has updated their guidelines on what constitutes high blood pressure—high blood pressure is now defined as 130/80 compared to the previous 140/90.
New research shows that infections could trigger a stroke in pregnant women during childbirth. Although maternal strokes are rare---only about 30of every 100,000 pregnancies---the fatality rate is extremely high. Stroke is one of the major causes of maternal death in the United States and has been a topic of growing concern among doctors and researchers alike.